Dr. Spiera's approach to PMR treatment - prefers methylprednisolone - rapid taper over 16 weeks - consider GC sparing therapy (MTX, IL-6i) @Rheumnow #RNL2023 https://t.co/EtlDZm1RSb https://t.co/cZSYwYRKNM

• https://bit.ly/3MkYmGq

IL-6 for PMR SPARE and SEMAPORE (Toci), SAPHYR (Sari) 2/2023: FDA approves sarilumab for PMR for inadequate response to corticosteroids or unable to taper off Robert Spiera @RheumNow #RNL2023 https://t.co/gpBYXhguaV https://t.co/7tU1VBUb6F

• https://bit.ly/43kWggL

Cochrane metanalysis of antidepressant use in managing chronic pain shows they dont work, with the small exception, duloxetine - at standard dose (60 mg) it was effective, but no benefit to using a higher doses https://t.co/SReueTu4VV https://t.co/ki0snBMS3z

• https://bit.ly/433wGwT

"Ideally, you should get your TA biopsies within 2 weeks, but that's not always possible. Don't delay tx." @anisha_dua reminds us that bx can still be positive up to 8 weeks after steroid initiation. Just be aware of lesional changes with time. #RNL2023 https://t.co/uYBNrGzdQm https://t.co/Rvs0ewHzwb

• https://bit.ly/3IoH0qS

Allergic Drug - Induced Arthritis Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies. https://t.co/AmpWG2Siii https://t.co/PwEgVHfDu8

• https://bit.ly/3IpKgm7

MSK Symptoms from Dupilimab, an IL-4/13 Inhibitor A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab. https://t.co/xGPSA2oRis https://t.co/y7M42DlM7d

• https://bit.ly/45e7QvO

Brepocitinib in Active PsA Brepocitinib is a novel tyrosine kinase 2/JAK1 inhibitor and has been studied in patients with moderately-to-severely active psoriatic arthritis (PsA), showing impressive efficacy at both 16 weeks and 52 weeks. https://t.co/qzOVsLMkYe https://t.co/ouLyB131r8

• https://bit.ly/3IqRqXj

QD Clinic - Audience Vasculitis Questions from RNL23 Audience questions from the live RNL 2023 meeting and the session on EVOLUTION AND ADVANCES IN VASCULITIS held on March 18, 2023. https://t.co/mvimbucTnd https://t.co/uJzkZcbNLa

• https://bit.ly/3Mrs5xE

ICYMI: TNR - Vasculitis: Evolution and Advances This is a replay from the live RNL 2023 meeting and the session on EVOLUTION AND ADVANCES IN VASCULITIS held on March 18, 2023. https://t.co/OAI8NbSNes https://t.co/eDqqV9yZ9d

• https://bit.ly/3BDqAqW

TNF Inhibitors and Acne? A literature review found 47 refractory acne pts Rx w/ TNFi; noting partial improvement (94%) or clearance (40%) & only 6% w/ adverse events. 17 pts had new-onset acne after Rx w/ TNFi for a different inflamm Dx. Odd! https://t.co/duHEIHBMyK https://t.co/br8NQZQE2r

• https://bit.ly/3ocyOmO

The Schwartzman's (Monica and Sergio) discuss being in rheumatology as a family unit. We are so lucky in rheumatology to have many family connections! #RNL2023 @RheumNow https://t.co/hFbeGll2ut https://t.co/dfHnnbpNS8

• https://bit.ly/45bq0OC

Dr. Anisha Dua on Imaging in PMR: - US of shoulders to eval for bursitis can increase specificity - MRI better for pelvic girdle, but expensive - Consider PET if lack of response to steroids, r/o malignancy #RNL2023 @RheumNow https://t.co/tjhGlJPDWZ https://t.co/9h1FwfM0CP

• https://bit.ly/3WflJpm

Dr. Langford's take home for GPA. Remember to consider disease severity (will determine tx,) maintenance tx, and non-medical management including vaccination options for pts. #RNL2023 @RheumNow https://t.co/R6nrz7YXZr https://t.co/UVY0jDUGJ2

• https://bit.ly/3BDoJTa